Core Viewpoint - The recent policy announced by Trump to align U.S. drug prices with the lowest global prices could lead to a significant decrease in prescription drug prices in the U.S., potentially by 30% to 80%, raising concerns among pharmaceutical companies, especially those exporting to the U.S. [1][2] Group 1: Market Performance - As of May 13, 2025, the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index (930965) rose by 2.42%, with notable increases in stocks such as BeiGene (06160) up 4.15% and Innovent Biologics (01801) up 3.14% [1] - The Hong Kong Pharmaceutical ETF (159718) opened high and increased by 2.04%, with a latest price of 0.70 yuan, and a one-month cumulative increase of 3.32% [1] - The CSI Pharmaceutical and Medical Device Innovation Index (931484) increased by 0.87%, with stocks like East China Pharmaceutical (000963) rising by 2.23% [4] Group 2: Trading Volume and Liquidity - The Hong Kong Pharmaceutical ETF had a turnover of 1.72% during the trading session, with a transaction volume of 4.0999 million yuan, and an average daily transaction volume of 95.7602 million yuan over the past month [1] - The latest scale of the Medical Innovation ETF (516820) reached 1.588 billion yuan [4] Group 3: Index Composition - The top ten weighted stocks in the CSI Hong Kong Stock Connect Pharmaceutical and Healthcare Composite Index accounted for 60.54% of the index, including BeiGene (06160) and WuXi Biologics (02269) [5] - The top ten weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index represented 66.51% of the index, featuring companies like Hengrui Medicine (600276) and WuXi AppTec (603259) [8]

Core Points - The CSI Hong Kong Stock Connect Innovative Drug Index decreased by 3.3% to 706.45 points, with a trading volume of 17.018 billion yuan on May 12 [1] - Over the past month, the index has increased by 16.02%, 20.90% over the last three months, and 25.61% year-to-date [1] - The index consists of 50 listed companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect [1] Index Composition - The top ten weighted companies in the index are: - Innovent Biologics (11.31%) - WuXi Biologics (10.96%) - BeiGene (9.29%) - CanSino Biologics (9.15%) - CSPC Pharmaceutical Group (7.19%) - China Biologic Products (6.94%) - Hansoh Pharmaceutical (4.18%) - WuXi AppTec (3.90%) - Zai Lab (3.88%) - 3SBio (3.45%) [1] - The index is exclusively composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation [1] Industry Breakdown - The industry composition of the index includes: - Biopharmaceuticals: 46.61% - Chemical drugs: 30.42% - Pharmaceutical and biotechnology services: 21.65% - Medical commerce and services: 1.32% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2]

中国国际金融股份有限公司 关于 双润正安信息咨询（北京）有限公司 要约收购江苏浩欧博生物医药股份有限公司 之 中国国际金融股份有限公司（以下简称"中金公司"、"本财务顾问"）接受收购人双 润正安信息咨询（北京）有限公司（以下简称"收购人"、"双润正安"）委托，担任其要 约收购江苏浩欧博生物医药股份有限公司（以下简称"上市公司"、"浩欧博"）之财务顾 问，持续督导期为要约收购报告书公告日起至要约收购完成后的 12 个月止，即 2024 年 12 月 20 日至 2026 年 2 月 14 日。根据相关法律法规规定，本财务顾问出具 2025 年 第一季度（即 2025 年 1 月 1 日至 2025 年 3 月 31 日，以下简称"本持续督导期"）的持 续督导意见。 一、交易资产的交付或过户情况 简称"海瑞祥天"）及其一致行动人苏州外润投资管理合伙企业（有限合伙）（以下简 称"苏州外润"）、公司时任实际控制人 JOHN LI、WEIJUN LI、陈涛与双润正安及其 一致行动人北京辉煌润康医药发展有限公司（以下简称"辉煌润康"）签署《股份转让 协议》，约定海瑞祥天向辉煌润康协议转让其所持浩欧博 18,670,878 ...

Group 1 - The report highlights that the exosome industry is in its early stages of industrialization, with significant growth potential anticipated in the coming years [3][8][9] - Exosomes, which are nano-sized vesicles involved in intercellular communication, play crucial roles in tumor progression, immune regulation, and metastasis, with applications in early cancer detection and treatment guidance [3][8] - The global exosome market is projected to grow from USD 112.25 million in 2022 to approximately USD 1.5 billion by 2030, reflecting a compound annual growth rate (CAGR) of 32.75%, with around 30% of applications in oncology and 50% of revenue generated by biopharmaceutical companies [3][8] Group 2 - The report notes that there are currently at least 46 companies in China engaged in exosome research and development, focusing on areas such as separation, purification, detection, new drug development, delivery, and diagnostics [3][8] - The industrialization of exosomes is still in its nascent phase, with only a few products available in the disease diagnosis sector, while drug delivery applications remain in early development without any products on the market [9] - The report emphasizes that the lack of a clear competitive landscape presents substantial opportunities for new entrants in the exosome industry [9]

Group 1 - The Hong Kong stock market has seen a narrowing increase, with the Hang Seng Index rising by 0.6% and the Hang Seng Tech Index increasing by 0.7% [1] - Pharmaceutical stocks have experienced a decline, with CSPC Pharmaceutical Group falling nearly 5%, WuXi Biologics dropping by 4.6%, and China Biologic Products decreasing by over 3% [1]

Core Viewpoint - Hemophilia is a hereditary bleeding disorder primarily treated through factor replacement therapy, with significant advancements in drug development leading to increased demand and market growth in China [1][6][20]. Industry Definition and Categories - Hemophilia is characterized by a deficiency in clotting factors, leading to prolonged bleeding tendencies, and can be classified into Hemophilia A and B, with A being more prevalent [2][3]. Current Industry Status - The demand for hemophilia drugs is on the rise due to advancements in diagnosis and treatment, with a projected demand of 5.8236 million doses in 2024 and 7.3154 million doses in 2025, reflecting a growing market size from 5.361 billion yuan in 2024 to 5.856 billion yuan in 2025 [6][9]. Market Competition Landscape - Major domestic companies in the hemophilia drug market include Beijing Shenzhou Cell Engineering, Shandong Taibang Biological Products, Henan Hualan Biological Engineering, and Shanghai Raist Blood Products, among others [13][14]. Industry Development Trends - The hemophilia drug industry is expected to benefit from technological innovations and increased awareness, leading to a broader market outlook as more patients can afford treatment and government support for rare diseases grows [20].

Core Viewpoint - The Hang Seng Healthcare Index has shown positive performance, with significant increases in constituent stocks, indicating a potential recovery in the healthcare sector [1][3]. Group 1: Index Performance - As of May 9, 2025, the Hang Seng Healthcare Index rose by 0.33%, with notable increases in stocks such as Zai Lab (+7.38%) and WuXi AppTec (+3.23%) [1]. - The Hang Seng Healthcare Index ETF (159557) has increased by 16.06% over the past month, ranking first among comparable funds [1]. Group 2: Liquidity and Scale - The Hang Seng Healthcare Index ETF recorded a turnover rate of 4.41% with a transaction volume of 11.35 million yuan [3]. - The ETF's latest scale reached 260 million yuan, marking a one-year high, with shares totaling 215 million, also a one-month high [3]. Group 3: Valuation Insights - The latest price-to-earnings ratio (PE-TTM) for the Hang Seng Healthcare Index ETF is 23.83, which is in the 4.36% percentile over the past year, indicating a valuation lower than 95.64% of the time in the last year [3]. Group 4: Market Outlook - China Galaxy Securities notes that the pharmaceutical sector has undergone a prolonged adjustment, resulting in low overall valuations and underweight public holdings. The policy support for commercial insurance development in 2025 is expected to improve payment conditions marginally, benefiting innovative drugs and medical devices [3]. - The company anticipates a sustained recovery in the pharmaceutical market, with structural opportunities remaining, particularly in the innovative drug supply chain [3].

Core Viewpoint - The China-Hong Kong-US Technology Index has shown a recent increase of 16.93% over the past month, indicating a positive trend in the technology sector despite a slight decline of 2.72% over the last three months and a year-to-date increase of 4.73% [1] Group 1: Index Performance - The China-Hong Kong-US Technology Index opened at 4705.23 points [1] - The index is calculated using an equal-weighted methodology, reflecting the overall performance of high liquidity and high market capitalization technology companies listed in China and the US [1] Group 2: Index Holdings - The top ten holdings of the index include: SMIC (3.35%), Xiaomi Group-W (3.23%), BYD Company (3.13%), Innovent Biologics (2.67%), Alibaba (2.66%), Netflix Inc (2.52%), CanSino Biologics (2.52%), Tencent Holdings (2.33%), China Biologic Products (2.30%), and Avago Technologies Ltd (2.28%) [1] - The index is composed of companies from various exchanges, with the Nasdaq Global Select Market accounting for 40.80%, Hong Kong Stock Exchange for 35.55%, New York Stock Exchange for 22.12%, and Nasdaq Capital Market for 1.53% [2] Group 3: Sector Allocation - The sector allocation of the index shows that Information Technology comprises 39.80%, Consumer Discretionary 20.93%, Healthcare 14.20%, and Communication Services 14.16% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2]

Group 1 - The core viewpoint of the article highlights the significant growth and low valuation of the Hang Seng Medical Index ETF, indicating a potential investment opportunity in the healthcare sector [3] - The Hang Seng Medical Index ETF experienced a turnover of 5.22% during the trading session, with a transaction volume of 13.05 million yuan, and a scale increase of 38.30 million yuan over the past month [3] - The ETF's shares increased by 5 million over the past two weeks, reflecting strong demand [3] Group 2 - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Index is 24.24, which is in the 5.09% percentile over the past year, indicating that the valuation is lower than 94.91% of the time in the last year, suggesting a historical low [3] - As of May 7, 2025, the top ten weighted stocks in the Hang Seng Medical Index include WuXi AppTec, BeiGene, Innovent Biologics, and others, collectively accounting for 56.7% of the index [3] - According to Xinda Securities, the innovative drug sector is expected to show high investment value in the second quarter of 2025 due to positive industry dynamics and policy support, including expected outcomes from medical insurance negotiations and the recovery of the hospital market [3]

Investment Rating - The industry investment rating is "stronger than the market" indicating an expected performance that exceeds the market by more than 5% over the next six months [49]. Core Views - The chemical agents and blood products sectors are expected to perform outstandingly in 2024, with positive revenue and profit growth reported in the CXO and medical services (hospitals) sectors for Q1 2025 [4][5]. - The biopharmaceutical industry is anticipated to outperform the market overall [4]. Summary by Sections Industry Performance - As of April 30, 2025, 467 A-share biopharmaceutical companies reported their 2024 annual and Q1 2025 results. In 2024, 28 companies had revenue growth exceeding 30%, while 50 companies exceeded 20%, and 113 companies exceeded 10%. Approximately 220 companies reported positive revenue growth, while 246 experienced negative growth. On the profit side, 102 companies had profit growth over 30%, 132 over 20%, and 172 over 10%, with 218 maintaining positive profit growth and 249 facing negative growth [4]. - In Q1 2025, 24 companies reported revenue growth over 30%, 52 over 20%, and 109 over 10%, with 214 maintaining positive revenue growth and 251 reporting negative growth. For profits, 100 companies had growth over 30%, 120 over 20%, and 159 over 10%, with 220 maintaining positive profit growth and 240 facing negative growth [4]. Investment Strategies - Focus on "innovation," "going global," "equipment upgrades," and "consumption recovery." - **Innovation**: Invest in globally competitive innovative drugs and categories with significant market potential. Recommended companies include BeiGene, Dongcheng Pharmaceutical, and others [7]. - **Going Global**: Explore overseas markets for long-term opportunities, with companies like Mindray Medical and others highlighted [7]. - **Equipment Upgrades**: Expect support for medical equipment updates from central and local government financing, with companies like Mindray Medical and others recommended [7]. - **Consumption Recovery**: Anticipate recovery in quality sectors like ophthalmology and medical aesthetics, with companies such as Puri Eye Hospital and others suggested [7]. Key Companies to Watch - **Nocare Biopharma**: Expected to achieve over 1 billion yuan in revenue from its core product, with a 49% year-on-year sales increase. The company reported a gross margin of 86.3% and a significant reduction in losses [8]. - **Sihuan Pharmaceutical**: Strong fundamentals with core products maintaining growth, and a robust pipeline expected to yield multiple approvals from 2025 to 2027 [11]. - **China Biopharmaceutical**: Rapid revenue growth with an increasing share of innovative products, and a strong pipeline in oncology [13]. - **Aibo Medical**: Anticipated growth in high-end artificial lenses and recovery in consumption due to aging trends [23]. Industry News Highlights - BeiGene's Sonrotoclax NDA application has been accepted for review, indicating potential market entry for a new treatment for CLL/SLL [30]. - Novartis' Pluvicto has received acceptance for a new indication in China, expanding its market potential [31]. - The partnership between Fuhong Hanlin and Sandoz for HLX13 indicates a significant milestone in the commercialization of biosimilars [33].